 Neurotrope, Inc. Nasdaq: NTRP and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company Metuchen, focused on identifying, developing, acquiring, and commercializing innovative therapeutics for mens health conditions, today announced that the two companies have entered into a definitive merger agreement under which Metuchen and Neurotrope, Inc. Neurotrope will merge in an all-stock transaction resulting in a newly formed holding company to be renamed Petros Pharmaceuticals, Inc. Petros. Petros is expected to become a Nasdaq traded company focused solely on mens health conditions. Petros cornerstone product would be Metuchens Stendra avanafil for erectile dysfunction ED. Petros pipeline would include Metuchens recently in-licensed product H-100 for Peyronies disease, and it would include a business development program exploring various mens health products, including endothelial dysfunction, prostate cancer, psychosexual and psychosocial ailments, hormone health and substance use disorders. 